GHK-Cu: Coordination Chemistry, Matrix Remodeling, and What the Gene Data Actually Showed
GHK-Cu is unusual among catalog peptides in that it was not designed. It was found — in human plasma, as an activity, before anyone knew what molecule was responsible.
Pickart and Thaler (1973, Nature New Biology) were characterizing a factor in human serum that prolonged the survival of cultured normal liver cells. The active species turned out to be a tripeptide, glycyl-L-histidyl-L-lysine, present in plasma at low micromolar concentrations. The same group published a synthetic-tripeptide companion paper in Biochemical and Biophysical Research Communications the same year. Fifty-plus years later the molecule is still in active investigation, and the reason is the copper.
The copper is not a contaminant — it is half the molecule
The most common misreading of this compound is treating “GHK” and “GHK-Cu” as the same thing with a formatting difference. They are chemically distinct entities and they do not behave identically in an assay.
The GHK sequence presents a near-ideal donor set for Cu(II): the terminal amine nitrogen, the deprotonated backbone amide nitrogen, and the histidine imidazole nitrogen. Freedman and colleagues (1982, Biochemistry) resolved the solution structure of the glycyl-L-histidyl-L-lysine–copper(II) complex and described the square-planar coordination geometry that results. The lysine side chain sits outside the coordination sphere, which is why it is available for other interactions.
Pickart and colleagues (1980, Nature) had already proposed the functional consequence: the tripeptide acts as a physiological copper carrier, facilitating copper uptake into cells. Copper is a required cofactor for lysyl oxidase, which cross-links collagen and elastin, and for superoxide dismutase. A molecule that delivers copper with controlled affinity — tight enough to carry it, loose enough to release it — is doing something functionally different from either free copper salt or apo-peptide.
This has a direct experimental implication. Where a published method specifies GHK-Cu and apo-GHK is dissolved instead, or where the copper stoichiometry in the vial is not 1:1, the experiment being run is not the one in the paper being replicated.
Extracellular matrix: synthesis and controlled degradation
The best-characterized activity is remodeling of connective tissue, and the useful detail is that the effect is bidirectional rather than a simple “stimulates collagen” story.
Maquart and colleagues (1993, Journal of Clinical Investigation) implanted wound chambers in rats and reported that the GHK-Cu complex increased accumulation of connective tissue components in vivo — collagen, glycosaminoglycans and proteoglycans — at very low doses. That in vivo rodent result is the anchor for most of what followed.
The Siméon group then took the mechanism apart. Siméon and colleagues (1999, Journal of Investigative Dermatology) examined matrix metalloproteinase expression and activation in wounds and found the tripeptide-copper complex modulated them. Siméon and colleagues (2000, Life Sciences) showed the complex stimulated MMP-2 expression in cultured fibroblasts, and Siméon and colleagues (2000, Journal of Investigative Dermatology) reported modulation of glycosaminoglycan and small proteoglycan expression in the wound environment.
That combination — increased matrix deposition and increased expression of the proteases that break matrix down — is the interesting part. Scar tissue is what you get when deposition outruns remodeling. A compound that raises both arms is a candidate modulator of remodeling quality rather than a simple pro-fibrotic agent, and that framing is more defensible from the data than “it builds collagen.”
The gene-expression result, stated accurately
GHK is often described as “resetting gene expression,” which overstates a real and more interesting finding.
Campbell and colleagues (2012, Genome Medicine) were not studying GHK. They derived a gene-expression signature associated with emphysema-related lung tissue destruction from human lung samples, then queried a connectivity-map-style database of compound-induced expression signatures for molecules whose signature ran opposite to it. GHK came out of that unbiased screen. The group then tested it directly in cultured human fibroblasts, where GHK altered expression of the relevant genes and affected collagen contraction and assembly in a three-dimensional culture system.
That is a computational hypothesis followed by an in vitro confirmation in one cell type. It is a genuinely notable result and it is the origin of essentially every “GHK modulates hundreds of genes” claim in circulation. Pickart and Margolina (2018, International Journal of Molecular Sciences) review the accumulated gene data, and Pickart and Margolina (2015, BioMed Research International) review the broader pathway work. Both are reviews by the molecule’s original discoverer, which is worth knowing when weighting them.
Other preclinical endpoints
Canapp and colleagues (2003, Veterinary Surgery) applied topical tripeptide-copper complex to ischemic open wounds in a canine model and measured healing parameters — one of the few controlled animal studies outside the rodent wound-chamber paradigm.
Pyo and colleagues (2007, Archives of Pharmacal Research) worked with human hair follicles in vitro and reported effects of the tripeptide-copper complex on follicle elongation and dermal papilla cell proliferation. An isolated-follicle organ culture is a legitimate model and also a limited one; it is not a systemic result.
What the record does not support
Three honest limits, because a study designed around an overstated premise wastes reagent.
Almost all of the in vivo data is topical or local. Wound chambers, topical application, isolated follicles. The literature on systemic exposure in animal models is comparatively thin, and inferences from a local matrix effect to a systemic one are inferences, not findings.
The dose-response is not monotonic in every system. Copper complexes frequently show biphasic behavior — activity in a concentration window, with reduced or opposite effects above it, where redox chemistry begins to dominate. Anyone running a single concentration is likely to miss this. Run a curve.
Copper is redox-active. Cu(II)/Cu(I) cycling in the presence of reductants such as ascorbate generates reactive oxygen species. In a cell-culture medium with defined reducing conditions, that is a real variable that belongs in the controls rather than in the discussion section.
Verifying a copper peptide from a US supplier
GHK-Cu presents a specific analytical problem that ordinary peptides do not, and the US supplier market — reshuffled considerably over the past year as researchers re-qualified domestic sources — has a wide quality spread on exactly this point.
The blue color is an identity cue, not an assay. It tells you copper is coordinated somewhere. It tells you nothing about how much, or about the peptide’s purity.
What a serviceable certificate of analysis for this material shows:
- Peptide purity by RP-HPLC, with the chromatogram, not just a number.
- Identity by mass spectrometry. Note that the copper complex and the apo-peptide give different masses; the report should be explicit about which species was measured and under what ionization conditions.
- Copper content, quantified. ICP-MS or an equivalent elemental method. Assumed stoichiometry is not measured stoichiometry, and a 50mg vial with the wrong copper loading fails silently — everything looks right until the numbers do not replicate.
- Water content, because lyophilized hygroscopic material that has taken on moisture is being weighed inaccurately from the first aliquot.
- A batch number that matches the vial in your hand.
Maple Research Labs publishes a batch certificate for every listed item, including GHK-Cu 50mg, and holds any product without one off the catalog entirely. Orders ship domestically from Santa Barbara, same-day on business days — no international leg, no customs hold, and fewer hours of uncontrolled temperature for a material that does not benefit from sitting in a warm sorting facility. The company is a Wyoming entity selling only within the United States, with access restricted to 21+.
Handling
Store lyophilized material at -20°C or below, protected from light. Copper peptide solutions are more sensitive to oxidation and to pH excursions than most simple peptides; strongly alkaline conditions and the presence of competing chelators such as EDTA will strip or redistribute the copper and quietly change what you are testing. Prepare fresh, aliquot rather than freeze-thaw repeatedly, and note that a 50mg vial is a large mass relative to the micromolar working concentrations most of this literature uses — serial dilution accuracy, not vial size, is the dominant source of error in practice.
All products supplied by Maple Research Labs are for research use only. These materials are not for human use, are not for veterinary use, are not for consumption, and are not intended to diagnose, treat, or prevent any condition. They are sold exclusively to qualified researchers and institutions for in vitro and laboratory investigation. Nothing on this page describes or endorses administration to people.